[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"maintenance-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:maintenance-treatment":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100603543","phase-2-anlotinib-hydrochloride-capsules-in-maintenance-treatment-for-intermediate-high-risk-rhabdomyosarcoma-in-children-100603543",false,"NCT07137884","Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children","A Phase II, Multicenter, Randomized, Controlled Clinical Study of Anlotinib Hydrochloride Capsules as Maintenance Therapy for Intermediate-High Risk Rhabdomyosarcoma in Children","ALTER-02","Inclusion Criteria:1.Age ≥5 years old, ≤18 years old, no gender restrictions; 2.ECOG performance status (PS) 0-3 points; 3.The expected survival period is not less than 12 weeks; 4.with high-risk or intermediate-risk rhabdomyosarcoma with high-risk factors (high-risk factors are defined as age \\> 10 years, poor prognostic molecular features, or inoperable\u002Fradiotherapy-ineligible) confirmed by histopathology ; 5.Complete remission was achieved after first-line treatment. 6.Patients must have fully recovered from the acute toxic effects of all prior anticancer chemotherapy: 7.Myelosuppressive chemotherapy: at least 21 days after the last myelosuppressive chemotherapy (42 days if nitrosoureas were used previously); 8.Investigational drugs or anticancer therapies other than chemotherapy: should not be used within the first 28 days of the planned start of anlotinib . Patients must have fully recovered from clinically significant toxicity of the therapy; 9.Hematopoietic growth factors: at least 14 days after the last dose of long-acting growth factors or 3 days after the last dose of short-acting growth factors; 10.Immunotherapy: at least 14 days after completing any type of immunotherapy (except steroids), such as immune checkpoint inhibitors and tumor vaccines; 11.X-ray therapy (XRT): at least 14 days after local palliative XRT (small-scale oral); if other parenchymal bone marrow (BM) irradiation is performed, including previous radioiodinated metaiodobenzylguanidine (131I-MIBG) treatment, it must be completed at least 42 days; 12.Stem cell infusion without total body irradiation (TBI): No evidence of active graft-versus-host disease, and the patient must have completed at least 56 days after transplantation or stem cell infusion; 13.Laboratory tests during the screening period should meet the following conditions: Absolute neutrophil count ( ANC) ≥ 1.5 × 109\u002FL (ANC ≥ 1.0 × 109\u002FL if bone marrow involvement occurs) Platelet count ( PLT) ≥75 × 109\u002FL (PLT ≥50 × 109\u002FL if bone marrow involvement occurs) Bilirubin ≤ 1.5 times ULN Creatinine ≤ 1.5 times ULN (calculated according to the standard Cockcroft-Gault formula) ALT\u002FAST ≤ 3 times ULN (can be relaxed to 5 times ULN if liver metastasis is present) 14.Ability to comply with outpatient treatment, laboratory monitoring, and necessary clinical visits during study participation; 15.The parent\u002Fguardian of the child or adolescent subject is capable of understanding, agreeing to, and signing the Informed Consent Form (ICF) and applicable Child Assent Form before initiating any protocol-related procedures; and the subject is capable of expressing consent (where applicable) with the consent of the parent\u002Fguardian.\n\nExclusion Criteria:Patients with any of the following cannot be enrolled in this study :\n\n1. Hypertensive patients who are currently receiving combined treatment with two or more antihypertensive drugs;\n2. Patients with the following cardiovascular diseases: Myocardial ischemia or myocardial infarction of grade II or above, poorly controlled arrhythmia (including QTc interval ≥450 ms for men and ≥470 ms for women); Grade III to IV heart failure according to NYHA standards, or left ventricular ejection fraction (LVEF) \\\u003C50% as indicated by cardiac ultrasound examination;\n3. Patients with a history of or concurrent interstitial lung disease;\n4. Abnormal coagulation function (INR\\>1.5 or prothrombin time (PT)\\>ULN+4 seconds or APTT\\>1.5 ULN), bleeding tendency or receiving thrombolytic or anticoagulant therapy;\n5. Daily hemoptysis of two teaspoons or more before enrollment;\n6. Patients with clinically significant bleeding symptoms or a clear bleeding tendency within 3 months prior to enrollment, such as gastrointestinal bleeding, bleeding hemorrhoids, bleeding gastric ulcers, baseline fecal occult blood ++ or above, or vasculitis;\n7. Arterial\u002Fvenous thrombotic events occurring within 12 months prior to enrollment, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;\n8. Known hereditary or acquired bleeding and thrombotic tendencies (such as hemophilia, coagulation disorders, thrombocytopenia, hypersplenism, etc.);\n9. Long-term unhealed wounds or fractures (pathological fractures caused by tumors are not included);\n10. Patients who have undergone major surgery or suffered severe traumatic injury, fracture or ulcer within 4 weeks of enrollment;\n11. Factors that significantly affect oral drug absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction;\n12. Abdominal fistula, gastrointestinal perforation, or abdominal abscess within 6 months before enrollment ;\n13. Urinalysis indicates urine protein ≥++, and the 24-hour urine protein volume is confirmed to be ≥1.0 g;\n14. Serous cavity effusion (including pleural effusion, ascites, and pericardial effusion) with clinical symptoms requiring symptomatic treatment;\n15. Note: Asymptomatic patients with serous cavity effusion can be enrolled. Patients with symptomatic serous cavity effusion who have undergone active symptomatic treatment (anti-cancer drugs cannot be used to treat serous cavity effusion) and are judged by the researchers to be eligible for enrollment are allowed to be enrolled.\n16. Active infection requiring antimicrobial treatment (e.g., antibacterial drugs, antiviral drugs, excluding anti-hepatitis B treatment for chronic hepatitis B and antifungal drugs);\n17. Those with a history of psychotropic drug abuse and unable to quit, or those with mental disorders;\n18. Participated in other anti-tumor drug clinical trials within 4 weeks before enrollment;\n19. Patients who have previously or concurrently suffered from other uncured malignant tumors, except for cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer;\n20. Use of drugs or foods that are known strong CYP3A4 inhibitors within 7 days before the first dose, including but not limited to: atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinafil, ritonavir, saquinavir, telithromycin, troleandomycin, and voriconazole;\n21. Use of drugs known to be strong inducers of CYP3A4 within 12 days prior to the first dose, including but not limited to: carbamazepine, phenobarbital, phenytoin, rifabutin , and rifampicin;\n22. Pregnant or breastfeeding women; patients of childbearing potential who are unwilling or unable to take effective contraceptive measures;\n23. The researcher determines other situations that may affect the conduct of the clinical study and the determination of the study results.\n24. When virological testing during the screening period shows any of the following:\n\nHBsAg positive and HBV DNA above the upper limit of normal Anti-HCV positive and HCV RNA positive HIV positive","ALL","5 Years","18 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a randomized controlled phase II clinical study aimed at evaluating the efficacy and safety of anlotinib hydrochloride in children with Intermediate-High -risk rhabdomyosarcoma. The study enrolled children with rhabdomyosarcoma confirmed by histopathology, with a clinical risk classification of high or Intermediate-risk accompanied by high-risk factors (high-risk factors are defined as age \\> 10 years，Poor prognosis molecular characteristics or those who cannot undergo surgery\u002Fradiotherapy);One year of maintenance treatment with anlotinib can increase the duration of response and long-term survival.",[28,29],"Rhabdomyosarcoma Recurrent","Maintenance Treatment","NOT_YET_RECRUITING","2025-08-15",{"date":33,"type":34},"2025-08-22","ACTUAL",{"date":36,"type":22},"2025-10-01",{"date":38,"type":22},"2028-12-30",{"name":40,"class":41},"Sun Yat-sen University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100549998","phase-3-toripalimab-plus-anlotinib-for-the-maintenance-of-extensive-stage-small-cell-100549998","NCT06441344","Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","First-line Etoposide Combined With Platinum-based Chemotherapy Followed by Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell Carcinoma - A Randomized, Controlled, Multicenter Phase III Clinical Study","SCLC","Inclusion Criteria:\n\n* Male or female aged ≥ 18 and\\\u003C80 years old.\n* The ECOG score is 0-1 points (including 0 and 1 points), and the expected survival period is not less than 3 months.\n* Confirmed as small cell lung cancer (SCLC) by histopathology or cytology and diagnosed as extensive after systemic evaluation.\n* I have not received first-line treatment for ES-SCLC systemic chemotherapy or immune checkpoint inhibitors in the past.\n* Limited stage SCLC progresses to extensive stage SCLC after receiving previous radiotherapy and chemotherapy aimed at cure,at least 6 months of no treatment period is required after the last radiotherapy and\u002For chemotherapy treatment.\n* Patients with previous active brain metastases have stabilized after treatment and do not require immediate or planned brain intervention during the study period Transfer for local treatment.\n* According to the criteria for evaluating the efficacy of solid tumors (RECIST v1.1), enrolled patients should have at least one tumor throughout their body The tumor lesion can meet the following requirements: it has not undergone local treatment such as radiotherapy in the past and is at baseline Can be accurately measured, with a baseline maximum diameter of ≥ 10mm (if it is a lymph node, a minimum diameter of ≥ 15mm is required).\n\nLesions that have previously received local treatment (radiotherapy or other treatments), if the treatment is completed for at least 6 months If disease progression occurs later, the lesion in the area that has undergone local treatment can be considered a measurable lesion.\n\n* Patients should have sufficient bone marrow reserve function and no liver, kidney, or coagulation dysfunction, and laboratory tests should be conducted\n* The value must meet the following conditions:\n\n  1. Absolute neutrophil count ≥ 1.5 × 109\u002FL, and white blood cell count ≥ 3 × 109\u002FL;\n  2. Platelet count ≥ 100 × 109\u002FL;\n  3. Hemoglobin ≥ 90g\u002FL;\n  4. Serum creatinine (Cr) ≤ 1.5 x Upper limit of normal (ULN) or creatinine clearance rate (CrCl) ≥ 50ml\u002Fmin (for patients with serum creatinine\\>1.5 x ULN);\n  5. If there is no confirmed liver metastasis, AST and ALT ≤ 2.5 × ULN; If there is confirmed liver metastasis, AST,ALT ≤ 5 × ULN;\n  6. If there is no confirmed liver metastasis, total bilirubin ≤ 1.5 × ULN; If there is confirmed liver metastasis or patients with syndrome (high indirect bilirubinemia), total bilirubin ≤ 3 x ULN;\n  7. If there is no confirmed liver metastasis, alkaline phosphatase (ALP) ≤ 2.5 x ULN or ≤ 5 x ULN (bone metastasis)\n  8. Albumin (ALB)\\>30g\u002Fdl;\n  9. 24-hour urine protein quantification\\\u003C1g (if urine protein ≥ 2+, additional 24-hour urine protein testing is required)\n  10. Serum lipase or amylase ≤ 1.5 x ULN or\\>1.5 x ULN (clinical or imaging diagnosis of pancreas)\n  11. International standardized ratio (INR) ≤ 1.5, and activated partial prothrombin time (APTT)≤ 1.5 x ULN.\n* Female subjects with reproductive ability have a negative blood pregnancy result within 7 days before starting the study treatment, and are willing to From the time of signing the informed consent form until the end of the last medication use, abstain from sexual activity or take medication for a period of 6 months medically recognized and efficient contraceptive measures (such as intrauterine devices, condoms, etc.), but the use of hormones is prohibited Using similar drugs for contraception; Male subjects are willing to take informed consent from the time of signing until the end of the last medication use Within the next 6 months, abstain from sexual activity or use medically recognized and effective contraceptive measures (such as condoms),and during this period, no sperm will be donated;.\n* The subjects are able to understand and voluntarily sign a written informed consent form (the informed consent form must be completed before conducting the study) Sign before any program specified in the plan.\n* Be able to voluntarily complete the research procedures and follow-up examinations according to the requirements of the research protocol.\n\nExclusion Criteria:\n\n* Mixed small cell lung cancer diagnosed by histology or cytology;\n* A history of severe allergic diseases, severe drug (including unmarketed investigational drugs) allergies, or known adverse reactions to this medication Allergy to any component of the investigational drug: presence of etoposide, platinum based drugs (carboplatin\u002Fcisplatin), or anlotinib.Individuals who are contraindicated to the use of anlotide or Toripalimab;\n* Previously received treatment with immune checkpoint agonists (such as CD137 agonists) or immune checkpoint inhibitors.Preparation therapy (such as single\u002Fdual antibodies against CTLA-4, PD-1, PD-L1, LAG3, etc.) or anti VEGF targeted drugs;\n* Previously received curative radiotherapy (excluding those who met the inclusion criteria of 5), or before receiving study treatment.Has undergone extensive palliative radiotherapy within 4 weeks, or plans to undergo chest radiotherapy during the study period\n* Need or plan to undergo elective surgical treatment during the trial period;\n* Received the following treatments or medications before starting the research treatment:\n\n  1. Received important organ surgery (excluding puncture) within 28 days before starting the study and treatment Inspection;\n  2. Received attenuated live vaccine within 28 days prior to starting treatment;\n  3. Have used intravenous broad-spectrum antibiotics for at least 7 days within 14 days before starting the study treatment;\n  4. Starting the study on systemic corticosteroids (prednisone\\>10) received within 14 days prior to treatment Mg\u002Fday or equivalent dose of similar drugs or other immunosuppressive treatments; Except for the following situations External: Treatment with local, ocular, intra-articular, intranasal, and inhaled corticosteroids; short Regular use of glucocorticoids for preventive treatment (such as preventing contrast agent allergies);\n  5. Received palliative radiotherapy for bone metastases within 14 days prior to starting the study treatment;\n* Currently, there is spinal cord compression or superior vena cava syndrome;\n* Currently, there are clear cases of interstitial lung disease or non infectious pneumonia, except for those caused by local radiotherapy;\n* There are brain metastases in the midbrain, pons, medulla oblongata, spinal cord, meninges, and meninges, or symptomatic large brain metastases Brain or cerebellar metastasis (such as manifested as cerebral edema and\u002For progressive growth); Central nervous system conversion\n\nIndividuals limited to the brain and cerebellum can participate in screening if they meet the following conditions:\n\na. Asymptomatic brain metastases (asymptomatic central nervous system progressive symptoms caused by brain metastases, also not necessary) Using corticosteroids or antiepileptic drugs for treatment; b. Symptoms stabilize for at least 2 weeks after radiotherapy for brain metastases, and corticosteroids or antiepileptic drugs are discontinued Drug discontinuation for at least 2 weeks;\n\n* Evidence of significant coagulation disorders or other significant bleeding risks:\n\n  1. History of intracranial hemorrhage or spinal cord hemorrhage;\n  2. Patients with tumor lesions invading large blood vessels and having a significant risk of bleeding;\n  3. Within the 6 months prior to the start of the study treatment, there have been incidents of thrombosis or embolism (asymptomatic and none) Except for intramuscular venous thrombosis that requires treatment, there is no absorption during follow-up examination, or significant vascular disease is present (For aortic aneurysm, aortic dissection, etc. that require surgical repair);\n  4. Clinically significant hemoptysis or tumor development for any reason within the first 3 months prior to starting the study treatment Blood;\n  5. Within 14 days prior to the start of the study, use anticoagulant therapy for therapeutic purposes (with low prophylactic use) Excluding molecular weight heparin;\n* Past or current active autoimmune diseases or immunodeficiency, including but not limited to severe muscle disease Weakness, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammation Sexually transmitted bowel disease, antiphospholipid antibody syndrome, Wegener's granulomatosis, Sj ö gren syndrome, Grimm Barr syndrome Li syndrome or multiple sclerosis; Except for: a Autoimmune related hypothyroidism Subjects with a history of withdrawal and currently taking thyroid replacement hormone; b. Stable status receiving insulin treatment 30% of subjects with type I diabetes.\n* Lesions limited to subjects with eczema, psoriasis, chronic simple lichen, and vitiligo on the skin (if diseased)\n\nWhen the damage has already affected parts or organs outside the skin (such as psoriasis, arthritis, etc.), it cannot be included in the group:\n\ni. Fever of unknown origin\\>38.5 ℃ (fever caused by tumor can be included in the group);\n\n* Within 6 months prior to starting the study of drug therapy, the following situations occurred:\n\n  1. Suffering from congestive heart failure, severe\u002Funstable angina, cerebrovascular accident, New York, USA Cardiac insufficiency classified by the Society of Cardiology (NYHA) as Grade II or above (including Grade II), Or other structural heart diseases that have been determined by researchers to be at high risk;\n  2. History of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or abdominal abscess;\n  3. There is uncontrollable tumor related pain, and if painkillers are needed, they should be stable during screening A prescribed pain relief treatment plan; Asymptomatic metastatic lesions, if further grown, may lead to Causing functional impairment or stubborn pain (such as epidural metastases that are currently unrelated to spinal cord compression), If appropriate, local treatment should be considered before screening;\n* Within the 5 years prior to starting the research on drug therapy, if there were other active malignant tumors, local treatment may be necessary Except for malignant tumors that have been treated and cured (such as basal cell or squamous cell carcinoma of the skin, superficial or non malignant) Invasive bladder cancer cancer, cervical carcinoma in situ, breast intraductal carcinoma in situ, thyroid papillary carcinoma);\n* Individuals who have received allogeneic hematopoietic stem cell transplantation or organ transplantation in the past;\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS);\n* Syphilis antibody positive and active syphilis infection present;\n* Individuals with active pulmonary tuberculosis or a history of pulmonary tuberculosis infection that cannot be controlled after treatment;\n* 20 HBsAg or HBcAb positive, and HBV-DNA\\>2000 IU\u002FmL (for For patients with HBV DNA\\>500 IU\u002FmL, the subject must agree to at least 7 days prior to the start of the study drug Continuously receiving antiviral treatment other than interferon during the research period is necessary to participate in screening; HCV antibodies Positive and HCV-RNA higher than the lower limit of detection in the experimental center (if the center is unable to detect HCV) RNA, acceptable external hospital results, relevant reports should be provided);\n* Expected to receive any other form of anti-tumor drug treatment during the trial period;\n* Known to have a history of alcohol abuse, psychotropic substance abuse, or drug use;\n* Individuals with mental disorders or poor compliance;\n* Pregnant or lactating women\n* According to the judgment of the researchers, the basic condition of the subjects may increase their risk of receiving study drug treatment,Or confusion caused by the occurrence of toxic reactions and the explanation of AE;\n* Other researchers deemed it unsuitable to participate in this experiment;","80 Years",{"count":53,"type":22},136,[55],"PHASE3","This is a randomized, open, multicenter Phase III clinical study. A total of 136 participants are planned to be enrolled and randomly assigned to either the experimental group (platinum+etoposide → toripalimab plus anlotinib) or the control group (platinum+etoposide+ toripalimab → toripalimab) in a 1:1 ratio. The primary efficacy measures include PFS, while secondary endpoints include OS, DOR, ORR, DCR, progression free survival at 6 and 12 months, overall survival at 12 and 18 months, health-related quality of life (FACT-L), safety, etc. And in the III clinical study, tissue samples were collected before treatment, and tumor tissue and blood samples were taken from some patients after 3 cycles of maintenance treatment and treatment progression for single-cell sequencing and transcriptome sequencing to verify the underlying mechanism research",[49,29],[59,29,60,61],"ES-SCLC","Toripalimab","Anlotinib","2024-05-28",{"date":64,"type":34},"2024-06-04",{"date":66,"type":22},"2024-07-01",{"date":68,"type":22},"2030-05-01",{"name":70,"class":41},"Taizhou Hospital",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":42},"100535807","the-maintenance-treatment-of-itiva-in-aml-patients-100535807","NCT06256627","The Maintenance Treatment of \"ITIVA\" in AML Patients","A Multicenter, Single Arm Clinical Study on the Efficacy and Safety of the \"ITIVA\" Protocol in Patients With Complete Remission of AML at Initial Diagnosis","Inclusion Criteria:\n\n1. Male or female, ≥ 14 years old.\n2. According to the WHO (2016) diagnostic criteria, the diagnosis of newly diagnosed AML is met (excluding APL).\n3. After conventional induction and chemotherapy with at least two consolidation schemes (at least one cycle of the scheme containing medium dose or above of Cytarabine, or the scheme of \"vinecla combined with Azacitidine\" gets remission, and continues to use the scheme to consolidate at least 6-8 cycles), CR or CRI can be achieved.\n4. \\\u003C6 months from the last chemotherapy.\n5. Having sufficient organ functions: creatinine clearance rate ≥ 30 mL\u002Fmin; Bilirubin\\\u003C3.0 × Upper limit of normal value (ULN) (sufficient liver function level); Platelets ≥ 50 × 10\\^9\u002FL; Neutrophil count ≥ 1 × 10\\^9\u002FL in granulocyte stimulated hematopoietic therapy\n6. Whole body functional state score (ECOG) 0-2 points\n7. The subjects are willing and able to follow the process required by this protocol.\n\nExclusion Criteria:\n\n1. Have a history of APL.\n2. Morphologically recurrent or refractory AML patients.\n3. Previous history of prodromal hematological diseases or treatment-related AML.\n4. MRD positive patients are scheduled to undergo allogeneic hematopoietic stem cell transplantation within one month. Patients with negative MRD are scheduled to undergo allogeneic hematopoietic stem cell transplantation within 6 months. Patients who have previously received allogeneic hematopoietic stem cell transplantation.\n5. There is a history of AML active central nervous system involvement.\n6. HIV infected patients.\n7. Uncontrolled infection.\n8. Merge New York Heart Association\\>Level 2 Cardiovascular Dysfunction Status. Level 2 is defined as heart disease where the subject feels comfortable during rest, but regular physical activity can lead to fatigue, palpitations, breathing difficulties, or angina.\n9. With chronic Respiratory disease, continuous oxygen inhalation is required, with major medical history of kidney, nerve, spirit, endocrine, metabolism, immunity, liver, cardiovascular disease, or with any other medical condition that the investigator believes will adversely affect his\u002Fher participation in this study.\n10. Complicated with Malabsorption syndrome or other diseases that hinder the administration of drugs through the intestinal route.\n11. Evidence of other clinically significant uncontrollable systemic infections (viruses, bacteria, or fungi) that require treatment.\n12. There are mental illnesses\u002Fsocial situations that may affect research compliance.\n13. History of merging other malignant tumors under treatment\n14. There is a clinically significant medical history or any other reason that the researcher believes will hinder the subject's participation in this study, or make the subject unsuitable for receiving the study drug.\n15. There is a history of allergic reactions or significant sensitivity to the ingredients of the investigational drug (and its excipients) and\u002For other similar products.\n16. The subjects are not allowed to receive other anti AML treatments. Non tumor disease treatment drugs can continue to be used.\n17. Female subjects with Fertility need to take contraceptive measures.\n18. There have been venous or arterial thromboembolic events within the past 6 months.\n19. Other researchers believe that it is not suitable for enrollment.","14 Years",{"count":80,"type":22},130,[82],"NA","We apply for this clinical study to evaluate the efficacy of \"combined recombinant human interference'- α- 1b, interleukin-2, and thalidomide\" regimen in obtaining MRD positive AML patients in CR,as well as the efficacy of the \"Venentoclax and azacitidine\" regimen and the \"combined recombinant human interference'- α- 1b, interleukin-2, and thalidomide\" regimen in alternately maintaining the treatment of MRD negative AML patients. The study included two cohorts. The first cohort consisted of AML patients who obtained CR or CRi but MRD positive after induction chemotherapy and consolidation chemotherapy. They were randomly given two cycles of \"recombinant human interference'- α- 1b, interleukin-2, and thalidomide\" or \"VA\" regimen treatment, and the MRD conversion rates of the two groups were analyzed. In the second cohort , after induction chemotherapy and consolidation chemotherapy, AML patients with CR or CRi and negative MRD were obtained, and were given \"recombinant human interference'- α- 1b, interleukin-2, and thalidomide\", Venentoclax and Azacitidine triple alternative maintenance treatment, to analyze the impact of maintenance treatment scheme on long-term survival of aml patients.",[85,29,86,87,88,89,90,91],"Acute Myeloid Leukemia","Minor Residue Disease","Interferon-α-1b","Interleukin-2","Thalidomide","Venentoclax","Azacitidine","RECRUITING","2024-02-05",{"date":95,"type":34},"2024-02-13",{"date":97,"type":34},"2023-07-11",{"date":99,"type":22},"2027-05-01",{"name":101,"class":102},"Henan Cancer Hospital","OTHER_GOV"]